A Next Generation Stem Cell Company Investor Presentation: Cynata Therapeutics Limited June 2018
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information availabl e to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata Therapeutics , nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situa tion, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The distribution of this presentation may be restricted by law and you should observe any such restrictions. Fo Forwar ard looking stat atements This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptio ns and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future bus iness strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation). www.cynata.com Investor Presentation June 2018 2
In Inves estm tment Summary: a Phase II-ready biotech with a highly scalable, proprietary platform for producing commercial quantities of MSCs ▪ Cymerus TM platform enables production of high quality Mesenchymal Stem Cells at scale Scal alabl able, glo global bally ly app applicab licable le tec techn hnolo logy gy ▪ Fully patented process overcomes multiple issues with today’s on -market solutions ▪ All trial endpoints achieved to date: no adverse safety events, highly encouraging efficacy Ex Exce cell llent ent resu results lts from rom ▪ GvHD programme well positioned to progress to Phase II Phase hase I tri trial al in n GvHD GvHD ▪ Safety data enables Cynata to move directly to Phase II in other indications ▪ Cardiovascular disease identified as priority indication area for expanded trial pipeline Cle Clear ar pipel pipeline ne of hi high gh- ▪ Planning for Phase II programme in Critical Limb Ischemia (CLI) to commence in H2 2018 potent po tential al targ target et area areas s ▪ Compelling pre-clinical data in multiple other high-value target areas ▪ Pro-forma cash balance of $13.5m based on cash balance of $8.3m as at 31-Mar-18, Well-funded Wel ded to progress to progress reinforced by $5.2m placement of shares to leading institutional investor Fidelity clini linical al pro rogram gramme International on 30-May-18 ▪ Fujifilm hold licence option for GvHD – will pay all costs of all further development and Attracti Attra tive ve lic licensing nsing- commercialisation plus $60m in milestone payments plus royalties if exercised driv driven busin en busines ess m s mode del ▪ Licence agreements and strategic partners for other indications being explored ▪ Estimated $1.7bn revenue opportunity for MSC supplier for GvHD and CLI products alone Valuabl Valuable and and ac acti tive ve mar arke ket ▪ Over 850 clinical trials investigating the efficacy of MSCs across numerous indications ▪ Multiple pharma companies active in stem-cell M&A www.cynata.com Investor Presentation June 2018 3
Cynata has the only platform in the world to produce commercial quantities of Mesenchymal Stem Cells from a single source Today’s on -market MSC manufacturing Patented Cymerus Platform solution has a number of shortcomings overcomes shortcomings Sourcing cells from multiple donors leads to CONSISTENT PRODUCT QUALITY REGULATORY ✓ variability in the sourced cells , which is a ISSUES Single donor overcomes regulatory concerns major regulatory hurdle Massive cell expansion is required to create MAINTAINED PRODUCT EFFICACY REDUCED ✓ enough cells for therapeutic use, which may EFFICACY Cymerus overcomes need for excessive expansion result in reduced efficacy For more information Sur urgery req equired to o on the Cymerus sou ource MS MSCs from platform visit bon one e marrow Mult ultiple Complex Co Cell Ce Cynata’s website donors surgery exp xpan ansion www.cynata.com Investor Presentation June 2018 4
MSCs are a highly potent form of stem cell attracting significant clinical interest – and in need of a scalable commercial solution Gl Global bal c commerc ercial l po potent tential al, , wit with multi h multipl ple targ target et Mesenchymal Stem Cells (MSCs) are believed to play a areas area s po potent tential ally ly be benef nefiti ting ng from rom MS MSC C treatme treatment nt vital role in repair and regeneration Modulator of the immune system ✓ Secrete bioactive molecules and have immunosuppressive ✓ and immunoregulatory properties Over 85 Over 850 0 clin linical al tri trial als s inv nves esti tigat gating ng th the e eff efficac acy of y of Diabetes Diabetic GvHD Fistula complications foot ulcers MSCs Cs in n treati treating ng dise disease ases s hav have e be been en ini niti tiated ated 1 Number of MSC clinical trials (cumulative) 1000 750 500 Acute respiratory Brain cancer / Osteoarthritis Asthma distress syndrome Glioblastoma 250 0 MSCs were approved for for use use as s a th therapeutic ✓ Critical limb Crohn’s disease Heart attack treatment in Japan in tr n Sep eptember 201 2015 and Eur Europe ischemia in March 201 2018 www.cynata.com 1. www.clinicaltrials.gov (as at June 2018) Investor Presentation June 2018 5
Cynata’s goal is for its patented Cymerus platform to become the preferred solution for Big Pharma to commercially produce MSCs Precli Prec linical da data ta Phase Phase I I near near com omple letion, , Pha Phase se II II plan planned ed ✓ Fujifilm licence option ✓ Licence available A ‘hub and spoke’ business model GvHD Intention to license Cymerus across a range of target areas to maximise value Potential Pote al futu uture targ target ar areas Phas Phase II II plan anned ✓ Licence available ✓ Licence available Following successful GvHD Critica Cr itical Lim Limb b trial, a new indication will Ische hemia ia progress direct to Phase II www.cynata.com Investor Presentation June 2018 6
Recommend
More recommend
